Well researchedMetabolic & fat loss

Retatrutide

LY3437943

REC PPT-RETATRUTIDE // REV 2026-10-04 // assessment changes are logged, never silent

Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.

What it is

An investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

What it does

Adding glucagon-receptor activity to the incretin pathways is thought to increase energy expenditure alongside appetite suppression.

Does it work?

Phase 2 results reported average weight reduction higher than any previously trialled agent, which is why interest is intense. It remains investigational — not approved by the SFDA, FDA or EMA — and long-term safety data is not yet complete.

Claims vs data

Each marketing claim, tagged by what the evidence actually supports.

Largest weight loss of any trialled agent to date	partially true
Approved and available	overreach

Reference figures

Quoted from published reference material. These are not Peptuity recommendations.

Vial10 mg

Diluent2 ml

Listed dose0.5–1 mg

Units / 1 ml10–20

Open in the calculator — prefilled →

The evidence, counted

Live counts from Europe PMC and ClinicalTrials.gov.

Publications 927

Randomised trials 18

Clinical trials 18

Registered studies 33

927 publications indexed, but only 18 randomised controlled trials and 33 registered interventional studies. Human evidence exists but is thin.

SRC // EUROPE PMC + CTGOV // "Retatrutide" // FETCHED 2026-10-04 // 927 RECORDS

Most-cited literature

[01] 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Ave · Circulation 2025 · 1099 citations · DOI 10.1161/cir.0000000000001303
[02] Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. · Signal Transduct Target Ther 2024 · 826 citations · DOI 10.1038/s41392-024-01931-z
[03] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Ha · N Engl J Med 2023 · 826 citations · DOI 10.1056/nejmoa2301972
[04] Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. · BMJ 2024 · 449 citations · DOI 10.1136/bmj-2023-076410

Regulatory status

Formal, dated regulatory actions.

WADA — Prohibited List 2026

Prohibited in sport — WADA S0 (substance without any health-authority approval)

source →

Common questions

When will retatrutide be approved?

Unknown. Phase 3 trials are ongoing; until they read out and regulators review them, any date is speculation.

Why is it graded below the approved GLP-1 drugs?

Its headline results are phase 2. Impressive, but smaller and shorter than the phase 3 programmes behind semaglutide and tirzepatide, with long-term safety still incomplete.

Is the vialled retatrutide being sold online the trial drug?

No vialled product sold outside the trial programme is verified. The trial evidence attaches to the manufacturer’s controlled material, not to grey-market copies.

Related compounds

FDA approved